4D Molecular Therapeutics (NASDAQ:FDMT) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report issued on Thursday,Benzinga reports. They currently have a $36.00 price objective on the stock.

FDMT has been the subject of a number of other research reports. Leerink Partners reissued an “outperform” rating and set a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Chardan Capital increased their price target on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Royal Bank of Canada cut their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, BMO Capital Markets cut their target price on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, July 18th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $47.00.

4D Molecular Therapeutics Trading Up 10.1 %

NASDAQ FDMT opened at $8.83 on Thursday. The firm has a market cap of $458.90 million, a PE ratio of -3.10 and a beta of 2.82. 4D Molecular Therapeutics has a 1-year low of $7.32 and a 1-year high of $36.25. The stock has a 50-day moving average of $10.30 and a 200-day moving average of $17.09.

Institutional Trading of 4D Molecular Therapeutics

Large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in shares of 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares in the last quarter. nVerses Capital LLC bought a new position in 4D Molecular Therapeutics in the third quarter worth $40,000. Values First Advisors Inc. purchased a new position in 4D Molecular Therapeutics during the third quarter valued at $57,000. Quest Partners LLC boosted its holdings in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after buying an additional 5,745 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $239,000. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.